Skip to content

Study · Observational study · n = 226 · 2013

6 results

Methylene blue is associated with poor outcomes in vasoplegic shock.

Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW

Journal of cardiothoracic and vascular anesthesia22 Aug 2013Cited by 44 (Europe PMC)

PMID23972738 (opens in a new tab)DOI10.1053/j.jvca.2013.02.026 (opens in a new tab)PepBankPUB-23972738
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studySafety outcome

    In cardiac surgery patients with vasoplegia, methylene blue use was linked to higher in-hospital mortality.

    In plain wordsIn cardiac surgery patients with vasoplegia, methylene blue use was linked to higher hospital mortality than no methylene blue.

    Peptide
    Methylene blue
    Outcome
    IncreaseIn-hospital mortality
    Study

    n = 226

    Comparator
    Patients not given methylene blue
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    4.26
    receiving methylene blue, multiple logistic regression
    Odds ratio 95% CI
    1.49 to 12.12
    receiving methylene blue, multiple logistic regression

    Source sentences

    Summary
    The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia.
    5 context sentences
    Summary · context
    A multiple logistic regression model demonstrated that receiving methylene blue was an independent predictor of in-hospital mortality (p value: 0.007, OR 4.26, 95% CI: 1.49-12.12)
    Summary · context
    Retrospective analysis.
    Summary · context
    Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.
    Summary · context
    With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue.
    Summary · context
    Two hundred twenty-six patients were identified who met the inclusion criteria for the study.
  2. 02HumanObservational studySafety outcome

    In cardiac surgery patients with vasoplegia, methylene blue use was linked to more combined morbidities.

    In plain wordsIn cardiac surgery patients with vasoplegia, methylene blue use was linked to more combined complications than no methylene blue.

    Peptide
    Methylene blue
    Outcome
    IncreaseCompilation of morbidities
    Study

    n = 226

    Comparator
    Patients not given methylene blue
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    4.8
    receiving methylene blue, multiple logistic regression
    Odds ratio 95% CI
    1.85 to 12.43
    receiving methylene blue, multiple logistic regression

    Source sentences

    Summary
    The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia.
    5 context sentences
    Summary · context
    compilation of morbidities (p value: 0.001, OR 4.80, 95% CI: 1.85-12.43)
    Summary · context
    Retrospective analysis.
    Summary · context
    Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.
    Summary · context
    With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue.
    Summary · context
    Two hundred twenty-six patients were identified who met the inclusion criteria for the study.
  3. 03HumanObservational studySafety outcome

    In cardiac surgery patients with vasoplegia, methylene blue use was linked to more renal failure.

    In plain wordsIn cardiac surgery patients with vasoplegia, methylene blue use was linked to more kidney failure than no methylene blue.

    Peptide
    Methylene blue
    Outcome
    IncreaseRenal failure
    Study

    n = 226

    Comparator
    Patients not given methylene blue
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia.
    4 context sentences
    Summary · context
    Retrospective analysis.
    Summary · context
    Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.
    Summary · context
    With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue.
    Summary · context
    Two hundred twenty-six patients were identified who met the inclusion criteria for the study.
  4. 04HumanObservational studySafety outcome

    In cardiac surgery patients with vasoplegia, methylene blue use was linked to more hyperbilirubinemia.

    In plain wordsIn cardiac surgery patients with vasoplegia, methylene blue use was linked to more high bilirubin levels than no methylene blue.

    Peptide
    Methylene blue
    Outcome
    IncreaseHyperbilirubinemia
    Study

    n = 226

    Comparator
    Patients not given methylene blue
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    6.58
    receiving methylene blue, multiple logistic regression
    Odds ratio 95% CI
    2.91 to 14.89
    receiving methylene blue, multiple logistic regression

    Source sentences

    Summary
    The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia.
    5 context sentences
    Summary · context
    and hyperbilirubinemia (p value:<0.001, OR 6.58, 95% CI: 2.91-14.89).
    Summary · context
    Retrospective analysis.
    Summary · context
    Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.
    Summary · context
    With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue.
    Summary · context
    Two hundred twenty-six patients were identified who met the inclusion criteria for the study.
  5. 05HumanObservational studySafety outcome

    In propensity-matched cardiac surgery patients with vasoplegia, methylene blue use remained linked to morbidity.

    In plain wordsIn matched cardiac surgery patients with vasoplegia, methylene blue use remained linked to more complications than no methylene blue.

    Peptide
    Methylene blue
    Outcome
    IncreasePropensity-matched morbidity
    Study

    n: not reported in source

    Comparator
    Patients not given methylene blue
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using propensity score matching, the association with morbidity was again seen but the association with mortality was not found.
    3 context sentences
    Summary · context
    Retrospective analysis.
    Summary · context
    Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.
    Summary · context
    With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue.
  6. 06HumanObservational studySafety outcome

    In propensity-matched cardiac surgery patients with vasoplegia, methylene blue use was not linked to mortality.

    In plain wordsIn matched cardiac surgery patients with vasoplegia, methylene blue use was not linked to mortality compared with no methylene blue.

    Peptide
    Methylene blue
    Outcome
    No significant changePropensity-matched mortality
    Study

    n: not reported in source

    Comparator
    Patients not given methylene blue
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using propensity score matching, the association with morbidity was again seen but the association with mortality was not found.
    3 context sentences
    Summary · context
    Retrospective analysis.
    Summary · context
    Adult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.
    Summary · context
    With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.